BLISSGVS

Oct 7 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - RECEIVES TAX DEMAND OF 166.9 MILLION RUPEES FROM TAX DEPARTMENT

Source text: ID:nNSE7qpMNB

Further company coverage: BLIS.NS

(([email protected];))

Sept 30 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - APPOINTS NARSIMHA SHIBROOR KAMATH AS CEO

Source text: ID:nBSE7sZhBb

Further company coverage: BLIS.NS

([email protected])

July 29 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 430.4 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.07 BILLION RUPEES

Source text: [ID:]

Further company coverage: BLIS.NS

(([email protected];;))

July 2 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - GETS SHOW CAUSE FROM TAX DEPARTMENT OVER RECOVERY OF REFUND OF 66.4 MILLION RUPEES

Source text: ID:nBSE46BZkl

Further company coverage: BLIS.NS

(([email protected];;))

April 15 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• RISING PHARMA HOLDINGS GETS FINAL APPROVAL FROM USFDA FOR MESALAMINE SUPPOSITORIES

Source text: [ID:]

Further company coverage: BLIS.NS

(([email protected];;))

Jan 21 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• TO CONSIDER ISSUANCE OF SWEAT EQUITY SHARES

Source text: ID:nBSE7zTS7Z

Further company coverage: BLIS.NS

(([email protected];;))

July 24 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 207 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.84 BILLION RUPEES

Source text for Eikon: ID:nBSE2Py5qt

Further company coverage: BLIS.NS

(([email protected];))

Feb 16 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• APPROVED AN INTERNAL RESTRUCTURING OF FOREIGN SUBSIDIARIES OF COMPANY

Source text for Eikon: ID:nBSE2BQhKM

Further company coverage: BLIS.NS

(([email protected];;))

Sept 7 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• ASSISTANT COMMISSION OF STATE TAX MAHARASHTRA INITIATED SEARCH ON SEPT 6 AT CERTAIN PREMISES OF CO

• NO IMPACT ON OPERATIONS, OR ANY OTHER ACTIVITIES OF CO EXPECTED AS OF NOW

Source text for Eikon: ID:nBSEqz51y

Further company coverage: BLIS.NS

(([email protected];;))

** Shares of Indian drugmaker Bliss GVS Pharma BLIS.NS fall as much as 6.87% to 91.55 rupees in sharpest intraday slide since May 12

** Co posted more than 43% slide in consol net profit at 146.9 mln rupees ($1.78 million) for the quarter ended June 30, while rev slipped more than 11% to 1.60 bln rupees

** Stock on track for fourth consecutive session of losses

** More than 400,00 shares changed hands by 10:09 a.m. IST, 0.8X 30-day avg

** BLIS has risen 28% so far this year

($1 = 82.4425 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Aug 1 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• INDIA'S BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 146.9 MILLION RUPEES VERSUS PROFIT 257.2 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.6 BILLION RUPEES VERSUS 1.89 BILLION RUPEES

Source text for Eikon: ID:nBSEjtHVV

Further company coverage: BLIS.NS

(([email protected];;))

June 15 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• GOT ESTABLISHMENT INSPECTION REPORT FOR PALGHAR UNIT FROM US FDA

• US FDA AGENCY ASSIGNED INSPECTION CLASSIFICATION OF FACILITY AS VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE24NSlj

Further company coverage: BLIS.NS

(([email protected];;))